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INTRODUCTION 
Moxalactam is a semi-synthetic beta-laetam antimicrobial agent 
currently undergoing Phase III clinical trials in human subjects (see 
Figure 1), In vitro studies demonstrate that moxalactam is effective 
against most gram-positive and gram-negative organisms, except 
* 
Streptococcus, Group'D, The drug is excreted almost entirely by 
renal mechanisms, Moxalactam is 38 to 50% plasma protein bound, based 
* 
o n iE y l t r o studies. 
The elimination half-life of moxalactam is two to three hours in 
patients with normal renal function, and 19 hours in patients with 
* 3 9 
end-stage renal disease. 5 ' No investigations thus far have deter-
mined the hemodialyzability of moxalactam. Pharmacokinetic data of 
moxalactam in renal failure patients are important not only to provide 
adequate dosage guidelines for therapeutic efficacy, but also to pre-
vent potential dose-related neurologic, hematologic, and renal 
4 5 7 8 11 
toxicities that have been reported with other cephalosporins. ' ' ' ' ' 
PURPOSE 
The purpose of this study was: to determine the pharmacokinetic 
parameters of moxalactam in patients with severe renal impairment, 
undergoing hemodialysis therapy; to determine the effect of hemodialysis 
on the pharmacokinetic parameters; to develop appropriate guidelines for 
dosing moxalactam In hemodialysis patients. 
LY127935: Investigators manual. Eli Lilly Laboratories, Indianapolis, 
Indiana, 1979. 
2 
MATERIALS AND METHODS 
Subject Selection 
The pharmacokinetics of moxalactam were studied in five volunteer 
subjects and two infected patients (see Table I). All subjects were 
at least 15 years of age and receiving hemodialysis therapy. Subjects 
1 through 6 had chronic renal failure and required maintenance hemo-
dialysis. Subject 7 had acute renal failure secondary to trauma. 
Informed written consent was obtained from all subjects (see Appendix 
A). Subject 7 was comatose, thus informed consent was obtained from 
his next of kin. 
Patients were excluded from the study for any one of the following 
criteria: concurrent administration of a second systemic antimicrobial 
agent during the study; systemic antimicrobial therapy within one week 
prior to the study; a known history of allergic reactions to peni-
cillin or cephalosporin antibiotics; pregnancy. 
A complete blood count with differential and platelet count, and 
a blood chemistry series were performed within 72 hours prior to the 
start of the study, and within 24 hours after the end of the study 
(see Tables IIA and IIB). 
Study Design 
Subjects 1 through 5 received a single 2 gram dose of moxalactam 
administered intravenously over 2 minutes. Subject 6 received 2 grams 
initially and 1 gram every 12 hours, and subject 7 received 2 grams 
every 12 hours for treatment of an infection. A heparinized needle 
was used as an access site for blood sampling in subjects 1 through 6 
while an arterial catheter was used in subject 7. The first 1 to 2 mis 
3 
of blood were discarded to clear heparin from the needle prior to ob-
taining the sample for antibiotic analysis. Three ml of blood were 
collected for each sample. A solution of 100 units heparin sodium per 
ml of 0.9% normal saline solution was instilled into the heparinized 
needle to maintain patency between sampling intervals. 
Samples were obtained from each subject prior to the administra-
tion of the drug and at 5, 10, 15, 30 minutes, 1, 2, 4, 6, and 8 hours 
after the initial dose. The subjects who received a single dose of 
the drug also had samples drawn at approximately 24 hours after the 
dose, just prior to the initiation of hemodialysis therapy. Three 
additional blood samples were collected on subjects 4 and 5 between 
19 and 24 hours after the dose. They were drawn 90 minutes apart. 
On all subjects blood samples were obtained pre-dialysis and 
immediately after the end of dialysis. Dialyzer input and output 
samples were obtained at 1, 2 and 3 hours after the start of hemo-
dialysis. All of the dialysate was collected. The total volume was 
measured and two 3 ml aliquots were obtained for analysis. Each 
patient was dialyzed on the equipment that they routinely used. 
All blood samples obtained were placed in an empty vacutainer 
and centrifuged for 5 rain at 1000 g in a Model K International 
csntiirxf ll^S • The serum was then transferred by pipette into empty, 
pre-labeled vacutainers, and frozen at -70°C. This procedure was 
completed within 60 minutes after collecting the specimen. The 
samples were assayed within 4 days after collection. 
Assay Method 
Moxalactam levels were determined by a microbiological assay 
2 
procedure using the modified method described by Bennett et al (see 
Appendix. B). All samples were assayed five times with five control 
samples. Standard solutions' were prepared by diluting moxalactam 1000 
mcg/ml to 500 mcg/ml with 1% sodium phosphate buffer, pH 6.0. 
Further dilutions were made with human serum from a single known donor 
to obtain concentrations of 2.5, 10, 20 and 50 mcg/ml. These dilu-
tions were made with normal saline when the dialysate samples were 
analyzed. 
Serum samples with drug concentrations that fell above the range 
of the concentration of the control samples were diluted 1 part 
sample in 9 parts normal serum before analysis. Since dialysate 
samples fell below the control concentrations, 1 ml of each dialy-
sate sample was lyophilized then reconstituted with 0.2 ml sterile 
water prior to analysis. 
Pharmacokinetic Analysis 
Serum concentration versus time curves were visually inspected 
to determine if the data best fit a one-compartment or two-compartment 
model. The data in the elimination phase were subject to linear re-
gression analysis using the method of least squares, as determined 
by a curve fitting program (Hewlett-Packard, HP-67). The negative 
slope of this regression line represented the elimination rate con-
stant (or beta for the two-compartment model). Since the data best 
fit a two-compartment model, the distribution rate constant (alpha) 
6 12 
was determined by the method of residuals. * The rate constants, 
5 
half-lives, volumes of distribution and clearance were calculated 
6 12 
according to accepted methods ' (see Appendix C), Data collected 
during hemodialysis was analyzed by a one-compartment model. 
Statistical Analysis 
Correlation analyses were performed on some of the data collected 
during hemodialysis. A programmable calculator was used to calculate 
2 
the coefficient of determination (r ) values. Using this value, 
significance was determined using a two-tailed t-test for signifi-
cance. The analyses were used to validate relationships that were 
expected to have a positive correlation. 
RESULTS 
The seven subjects admitted to the study ranged from 20 to 65 
years of age with a mean of 40.3 years. Six of the subjects were 
male and one was female. They ranged in weight from 49.0 kg to 84.0 
kg with a mean of 66.5 kg. Subjects 1 through 6 had chronic renal 
failure requiring hemodialysis therapy, but only subject 6 was surgi-
cally anephric. Subject 7 had acute renal failure for which he was 
receiving hemodialysis therapy. 
By visual analysis the data appeared to exhibit two-compartment, 
first order kinetics. All data were analyzed by a two-compartment 
open model except for the data from subject 1. Ho distinct distribu-
tion phase could be identified from his data. 
Individual serum concentrations are presented in Tables III , IV, 
and V, The calculated mean (± SD) serum concentration 24 hours after 
the dose would be a mean of 59.8 ± 13.0 meg/ml. Data from subjects 6 
and 7 were extrapolated. The mean observed peak serum concentration 
6 
at 5 minutes after the dose was 179.3 ± 49.5 mcg/ml. This was during 
the distribution phase and does not reflect the concentration of drug 
in the central compartment once pseudoequilibrium between the central 
and peripheral compartment is established. The extrapolated theoreti-
cal peak serum concentration in the central compartment at time zero 
is a mean of 127 + 31.0 mcg/ml. ("Peak serum concentration" when 
used in this text shall be the extrapolated value, discount tog the 
distribution.) Distribution appeared to be complete in most subjects 
by 4 hours after the dose. Graphical representations of the serum 
concentration versus time data on each subject are shown in Figures 
2 through 8, with a graph of the mean data shown in Figure 9. 
The pharmacokinetic parameters for each subject and the mean 
data are presented in Tables VIA and VIB. The mean beta elimination 
half-life was 27.5 ± 15.4 hours. The mean alpha distribution half-
life was 25.8 ± 25.8 minutes. The mean volume of distribution at 
steady state (Vd ) was 0.279 ± 0.093 1/kg, while the mean plasma ss 
clearance was 7.26 ± 3.06 ml/kg/hr. These calculations were based 
on total body weight. 
No subject reported any side effects of the drug except for 
subject 3 who said he could taste the drug. No change In laboratory 
parameters were noted pre- and post-study in any subject. 
The serum concentrations that were collected during hemodialysis 
are presented in Table VII. The characteristics of each dialyzer are 
listed in Table VIII. The acrylnitrile membranes (as used on subject 
6) are considered to be high-flux dialyzers and are expected to have 
a higher rate of clearance per unit of surface area than those 
© * 
dialyzers with Cuprophan membranes. 
The dialyzer extraction ratios calculated for each patient are 
presented in Table IX. The mean ratio was used for the calculation 
of clearance while on dialysis. Table X summarizes the pharmacokine-
tic parameters for each patient during hemodialysis. The half-life 
of moxalactam while on hemodialysis was 5.78 ± 2.56 hours. The mean 
plasma clearance was 27.4 ± 4.2 ml/min. 
Table XI presents the dialysate data collected. With the 
dialysis equipment used on subject 6, it was possible to collect the 
ultrafiltrate separately. The concentration in the ultrafiltrate was 
8.72 meg/ml. This was similar to the 7.25 mcg/ml measured in the -
total dialysate collected. 
Subject 7 was critically ill during the course of the study. 
He required numerous procedures that precluded obtaining blood 
samples at the desired times. The data used to calculate the elimi-
nation rate constant (beta) were collected after the third dose. Data 
collected after the first dose were used to calculate an alpha value. 
The B constant reported is calculated as if the elimination data 
were collected after the initial dose. Serum samples used to calcu-
late hemodialysis pharmacokinetic parameters were collected at a 
different time than the dialysate samples. The same dialysis equip-
ment was used both times. 
Based on the performance characteristics data available from the 
manufacturer of each dialyzer. 
Figures 17 through 19 show the results of the correlation 
analyses performed. Figure 17 represents the correlation between the 
pre-dlalysis serum concentration of moxalactam and the amount of drug 
recovered in the dialysate. This was a significant correlation 
(r2=0.92Q9, p <0.001). 
Figure 18 shows the correlation between the ratio of total drug 
recovered to pre-dialysis serum moxalactam concentrations versus the 
time on hemodialysis. The ratio was used to correct for the fact 
that each subject had a different amount of drug in their body at 
2 
the start of dialysis. This correlation was also significant (r = 
0.8378, p <0.01). 
The correlation between dialyzer surface area and clearance 
during hemodialysis is shown in Figure 19. This was a significant 
2 ® correlation (r =0.8053, p <0.025). Only dialyzers with Cuprophan 
membranes were used in this analysis since the acrylnitrile membrane 
has a greater clearance rate per unit of membrane surface area. 
DISCUSSION 
The half-life of moxalactam is considerably prolonged in patients 
with end-stage renal disease. The mean elimination half-life in this 
study was 27.5 hours with a range from 14.8 to 54.0 hours. 
If the data from subjects 6 and 7 are excluded, the mean half-life 
is 18.1 hours. Subjects 6 and 7 who had the longest half-lives of the 
subjects In this study were critically ill and were receiving 
moxalactam for treatment of a severe infection. The other five sub-
jects were volunteers who received a single dose. Subjects 6 and 7 
also had a different etiology of their renal disease than the rest of 
9 
the subjects. The patient population is too small to draw any con-
clusions, but it is possible that being critically ill or having a 
specific type of underlying renal disease alters the pharmacokinetics 
of moxalactam. 
3 
Bolton et al also examined the pharmacokinetics of moxalactam 
in renal failure patients. Their data were based upon single dose 
administration of the drug in healthy volunteers with varying de-
grees of renal failure. Those patients with a creatinine clearance 
<_ 5 ml/min had a mean elimination half-life of 19.3 ± 8.73 hours with 
a range from 7.99 to 34.9 hours. This is comparable to the half-life 
observed in this study in subjects 1 through 5 who were also healthy 
volunteers receiving a single dose of moxalactam. 
Hemodialysis increased the plasma clearance of moxalactam almost 
fourfold. The mean half-life during hemodialysis in these patients 
is 5.78 hours. This profile is similar to that of other cephalo-
sporins except cefamandole (see Appendix D). 
The correlation analyses validated the expected relationships 
within the data. Although these were significant, many other factors 
contribute to this. For instance in Figure 17, the point that fell 
furthest from the line is from subject 7. He was only on hemodialysis 
for 3 hours while the other subjects were diaiyzed from 4 to 5 hours. 
If a wider range of length of time on dialysis were used this re-
lationship might not be significant. It would be expected that the 
longer the subject is on hemodialysis the greater the percentage of 
drug recovered in relation to the amount in the body, as demonstrated 
by the correlation in Figure 18. It was also expected that the greater 
10 
the surface area of the Cuprophan® membranes the greater the clearance 
rate as demonstrated In Figure 19, 
The current dosage recommendation for moxalactam is 250 to 500 
rag every 12 hours for mild uncomplicated infections and 500 mg to 2 
grams every 8 to 12 hours for moderate to severe infections. 
Based on the data from this study, patients with renal failure 
should be given a loading dose of moxalactam. If a loading dose Is 
not given, it would take these patients four days or longer to reach 
steady state levels. A loading dose of 1 to 2 grams would give 
"peak serum concentrations" of greater than 50 to 100 mcg/ml in most 
patients. 
By extrapolating the single dose data collected in this study, 
guidelines for maintenance doses were determined. A maintenance dose 
of 500 mg to 1 gram should be given every 24 hours. At steady state, 
the subject in this study with the shortest half-life would be ex-
pected to have theoretical peak serum concentrations between 50 and 
100 mcg/ml with trough levels between 16 and 32 mcg/ml. The subject 
with the longest half-life would be expected to have theoretical peak 
serum concentrations between 80 and 160 mcg/ml with trough levels be-
tween 60 and 120 mcg/ml. Based on the minimum inhibitory concentra-
tion (MIC) data for moxalactam (see Appendix E), these levels should 
be adequate to treat most infections except for many Pseudomonas 
strains. In this case, a predicted loading dose of 3 grams with a 
maintenance dose of 2 grams every 24 hours should maintain adequate 
levels. 
11 
In patients who are hemodialyzed, a maintenance dose of moxalac-
tam is required post-dialysis. The maintenance dosage schedule should 
then be continued from that dose thereafter. 
CONCLUSION 
Moxalactam is a cephalosporin-like antibiotic with broad spec-
trum antimicrobial activity. The drug is known to be excreted 
primarily renally. This study examined the pharmacokinetics of 
moxalactam in seven subjects with severe renal disease requiring hemo-
dialysis therapy. The mean half-life of moxalactamwas 27.5 hours 
while the half-life during hemodialysis was 5.78 hours. Based on 
the data collected, a loading dose of moxalactam would be necessary 
to initiate therapy in this patient population so that adequate drug 
concentrations are rapidly achieved. Maintenance doses should be given 
every  24 hours., In patients receiving hemodialysis therapy, a 







Figure 1. The structure of moxalactam, 
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Figure 2, Graph of the data collected from Subject 1 after subject received 2 grams of 
moxalactam by intravenous bolus on a day when the subject was not dialyzed. 
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Figure 3 Graph of the data collected from Subject after subject received 2 grams of 
moxalactam by intravenous bolus on a day when the subject was not dialyzed. 
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Figure 4 Graph of the data collected from Subject after subject received 2 grams of 
moxalactam by intravenous bolus on a day when the subject was not dialyzed. 
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Figure 5, Graph of the data collected from Subject after subject received 2 grams of 
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Figure 6. Graph of the data collected from Subject 5 after subject received 2 grams of 
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Figure 7. Graph of the data collected from Subject 6 after subject received 2 grams of 
moxalactam by intravenous bolus on a day when the subject was not dialyzed. Dotted line 
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Figure 8. Graph of the data collected from Subject 7. Dotted line indicates the extra-
polated portion of the line. Data labeled A were collected after the initial dose of 2 grams 
of moxalactam administered by intravenous bolus, while the data labeled B were collected 
after the third dose administered. These data were collected when the subject was not 
being dialyzed. 
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Figure 9. Graph of the mean of the data collected, 
portion of the line. 
Dotted line indicates the extrapolated 
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Figure 10. Graph of the data collected during hemodialysis 
on Subject 1. Data labeled A represent the. concentration in 
serum entering the dialyzer, while data labeled V represent 
the concentration in serum leaving the dialyzer, 
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Time (hours) 
Figure 11. Graph of the data collected during hemodialysis 
on Subject 2. Data labeled A represent the concentration in 
serum entering the dialyzer, while data labeled V represent 













Figure 12. Graph of the data collected during hemodialysis 
on SuBject 3. Data labeled A represent the concentration in 
serum entering the dialyzer, while data labeled V represent 
the concentration in serum leaving the dialyzer. 
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Figure 13. Graph of the data collected during hemodialysis 
on Subject 4. Data labeled A  represent .. the concentration in 
serum entering the dialyzer, while data labeled V represent 
the concentration in serum leaving the dialyzer, 
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Figure 14. Graph of the data collected during hemodialysis 
on Subject 5, Data labeled A  represent the concentration in 
serum entering the dialyzer, while data labeled V represent, 
the concentration in serum leaving the dialyzer, 
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Figure 15. Graph of the data collected during hemodialysis 
on Subject 6, Data labeled A represent- the concentration in 
serum entering the dialyzer, while data labeled V represent 
the concentration in serum leaving the dialyzer, 
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Figure 16. Graph of the data collected during hemodialysis 
on Subject 7. Data labeled A represent the concentration in 
serum entering the dialyzer, while data labeled V represent 
the concentration in serum leaving the dialyzer, 
r 
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Figure 17. The correlation between the total amount of drug recovered in the dialysate ^ 
and the serum concentration of moxalactam at the start of dialysis was significant m 
(r =0.9209, p <0.001). 
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Time on dialysis (hours) 
Figure 18. The correlation between time on dialysis and 
the ratio of total drug recovered in the dialysate to 
serum concentration of moxalactam taken just prior to 
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Figure 19 , The correlation between dialyzer surface area 
and clearance during hemodialysis was significant (r2=0.8053» 
p <0.025), Only the dialyzers with Cuprophan® membranes were 
used in this analysis. 
TABLES 
Table I. Subject characteristics 









Reason for renal failure 
1 M 21 79.5 84.0 185 Chronic glomerulonephritis 
2 F 33 50.0 49.0 158 Chronic glomerulonephritis 
3 M 59 77.3 95.3 183 Polycystic kidney disease 
4 M 65 75.0 55.3 180 Chronic glomerulonephritis 
5 M 23 54.5 52.3 158 Chronic glomerulonephritis 
6 M 61 77.3 63.6 183 Surgically anephric 
7 M 20 77.3 66.3 183 Acute renal failure secondary to 
trauma 
IBW = ideal body weight calculated according to the following equation: 
Female: 45.5 kg/5 ft of height + 2.3 kg/inch over 5 feet 
Male: 50 kg/5 ft of height +2.3 kg/inch over 5 feet 
+TBW = total body weight 

















1 1 0 . 4 3 1 . 3 7 .2 361 141 4 . 2 101 38 1 1 . 1 
2 9 .7 30.6 6.4 190 133 3 . 2 97 25 5 . 5 
3 16,2 50 .7 5 . 4 230 137 4 , 3 94 43 9 .0 
4 U . 6 32 .5 6 , 3 289 137 4 . 5 99 25 5 . 5 
5 1 3 . 4 4 0 . 8 r c —* • —f 270 138 3 . 6 92 22 6 .7 
6 1 0 . 5 3 1 , 0 1 0 . 7 Adeq, 140 4.6 102 121 1 4 . 4 
7 11.2 3 1 . 0 25 .5 137 141 3 . 2 105 22 6 . 0 
Data are post-dialysis parameters, post-study. 
Abbreviations with normal ranges 
Hgb - hemoglobin 12.9-17.1 gm/dl K - potassium 3.3 - 5.3 mEq/ml 
HCT - hematocrit 39-51.1% CI - chloride 95-116 mEq/ml 
WBC - white blood count 3.6-9.9 k/cmm BUN - blood urea nitrogen 6-23 mg% 
PLT - platelet count 140-440 k/emni CR - serum creatinine 0.4-1.6 mg% 
Na - sodium 138-148 mEq/ml 
u> 


















1 9.8 7.8 0.4 5.9 3.7 140 9 21 
2 9.3 4.8 0,2 6,3 4.0 87 14 19 
3 11.8 2,7 0.4 7.4 4.2 160 17 20 
4 10,7 2.7 0.4 6,7 4.1 169 20 26 
5 9.2 4.8 0.5 8.6 5.1 86 88 176 
6 7.3 6.0 0.4 7.3 3.8 92 14 18 
7 8.1 0.9 18,7 5.4 3.0 161 6 -
Data are post-dialysis parameters, post-study . 
Abbreviations with normal ranges 
Ca - calcium 9. 3—11.1 mgl Alb. - albumin 3.8-5.0 gm% 
Phos - phosphorus 2.1-4.9 mg% Alk.P. - alkaline phosphatase 26-138 IU/L 
T.Bil. - total bilirubin 0-1.0 mg% SGOT - serum glutamate oxalacetate 
transaminase 1-51 IU/L 
T.Pr. - total protein 5.6-8.0 gm% SGPT - serum glutamate pyruvate 
transaminase 4-46 IU/L 
Table III, Serum moxalactam concentrations (meg/ml) after initial 2 gram dose given by intravenous bolus 
Subject 5 min 10 min 15 min 30 min 1 hr 2 hr 4 hr 6 hr 8 hr pre-dialysis 
time after 
dose 
1 148 131 165 95 137 112 120 107 101 45.7 23.0 hrs 
2 178 200 180 151 156 133 111 104 97 47.6 24.0 hrs 
3 240 207 162 129 109 125 125 102 120 52.3 23.95 hrs 
4 168 157 132 146 128 109 89.2 80.1 79.6 55.0 23.88 hrs 
5 254 255 227 209 192 163 134 158 133 73.3 23.52 hrs 
6 125 112 96.5 94.8 90.4 81.8 83.3 83.8 79.4 * -






















Dialysis data were not collected after the first dose. 
+Patient placed on dialysis one hour after dose. No further first dose data could be collected. 
Table IV. Additional serum concentrations obtained during the 


















Table V. Serum moxalactam concentrations after 2 gram dose 
* 
given by intravenous bolus: subject 7 
Serum Concentration 







Third dose patient received 
"^ Multiple procedures precluded drawing levels at desired 
times 
Table VIA. Pharmacokinetic parameters 
Rate Constants (hr _ 1 ) 
Subject 
Constants (mcg/ml) 






(min) % 3 (hour) 
1 — 137.7 - - 0.0467 0.96 - - - - 14.8 
2 50.3 134.7 0.8345 0.76 0.0431 0.99 0.0580 0.2003 0.6193 49.8 16.1 
3 263.9 148.4 10.78 0.91 0.0429 0.94 0.1183 6.797 3.908 3.60 16.1 
4 64.4 94.6 0.6385 0.85 0.0203 0.88 0.0334 0.2873 0.3881 65.4 34.1 
5 128.2 174.7 2.486 0.95 0.0364 0.95 0.0625 1.011 1.448 16.7 19.0 
6 29.8 88.7 2.646 0.76 0.0128 0.67 0.0171 0.6583 1.984 15.7 54.0 





















See Appendix C for definition and calculation of parameters 
+ 2 
r = coefficient of determination 
•k 
Table VEB. Pharmacokinetic parameters 
Volumes of Distribution (1/kg) 











mg-hr/1 Clearance (ml/kg/hr) 
1 - - - - 0.173+ 2954+ 8.06+ 
2 0.220 0.069 0.290 0.293 0.303 3186 12.8 
3 0.051 0.088 0.138 0.140 0.141 3484 6.02 
4 0.227 0.169 0.396 0.380 0.382 4761 7.59 
5 0.126 0.088 0.215 0.216 0.219 4850 7.89 
6 0.266 0.088 0.353 0.354 0.354 6943 4.53 

















* See Appendix C for definition and calculation of parameters 
+ 
Data were analyzed by one-compartment model; not included in calculation of mean values 
•p-o 
7< 













Time After Start 
of Dialysis 
1 45.7 34.5 26.0 24.9 22.0 24.9 19.8 18.5 4.91 hrs 
2 47.9 43.9 30.1 34.0 25.2 23.0 22.0 22.8 4.42 hrs 
3 52.3 45.9 44.1 45.9 31.9 40.5 32.4 26.7 5.00 hrs 
4 55.0 42.8 33,8 38.5 30.8 35.9 27.6 28.4 5.00 hrs 
5 73.3 60.3 41.7 47.5 38.8 42.0 32.4 27.4 5.00 hrs 
6 143 156 121 138 104 130 104 112 4.08 hrs 
7 186 180 143 143 133 150 121 + 3.00 hrs 
A = sample taken from blood entering dialyzer 
V = sample taken from blood leaving dialyzer 
Same as 3 hr A sample 
1 
Table ¥111. Dialyzer characteristics 
Subject Dialyzer model 
used 
Type of dialyzer Surfacg 
Area (m ) 




















































Table IX. Dialyzer extraction ratios 
Subject 1 hr 2 hr 3 hr Mean ± SD 
1 0.2463 0.1165 0.2040 0.1890 + 0.0662 
2 0.3144 0.2588 0.0435 0.2060 + 0.1431 
3 0.0392 0.3050 0.2000 0.1814 + 0.1339 
4 0.2103 0.2000 0.2312 0.2138 + 0.0159 
5 0.30845 0.1832 0.2285 0.2400 ± 0.0634 
6 0.2244 0.2464 0.2000 0.2236 + 0.0232 
7 0.2101 0.0610 0.1918 0.1543 + 0.0813 
A — V 
Ratio calculated by — j — . Data were collected at 1, 2, and 
3 hours after the start of dialysis 
Table X. Pharmacokinetic parameters during hemodialysis 

















1 0.1763 3.93 0.189 250 32.5 0.92 
2 0.1931 3.59 0.206 200 28.6 0.90 
3 ' 0.1287 5.38 0.181 225 20.1 0.91 
4 0.1228 5.64 0.214 200 28.9 0.96 
5 0.1946 3.56 0.240 170 24,2 0.99 
6 0.0664 10.4 0.224 200 30.9 0.75 









C^learance calculated by: extraction ratio* x blood flow rate x (1 - hematocrit) 
2 
+r = coefficent of determination 
Table XI. Dialysate data 
Subject Total Volume Time on Dialysis Cone, of Moxalactam Total Drug Cp pre-
of dialysate in dialysate Recovered dialysis 
(liters) (hours) (mcg/ml) (mg) (mcg/ml) 
1 1 4 0 . 0 4 .91 2 ,38 333 45.7 
2 1 3 4 . 6 4 ,42 2 .66 358 47 .9 
3 1 4 1 . 3 5 , 00 2,84 400 52 ,3 
4 1 3 8 . 8 5 , 0 0 3 , 3 0 455 55 .0 
5 142 .7 5 , 00 4 . 1 0 585 73 .3 
6 144 .6 4 , 08 7 ,25 1048 143 
7 1 1 5 . 9 3 . 0 0 5 .20 603 106 
APPENDIX A 
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CONSENT FOR PARTICIPATION IN INVESTIGATIONAL STUDY 
I. INFORMATION 
You are invited to participate in this drug study because of your 
kidney disease. The drug that we are investigating is a cephalosporin-
like antibiotic, named moxalactam. This drug has already been given 
to over 1,000 patients with good results and a high level of safety. 
To date, moxalactam appears as safe as other cephalosporin-like anti-
biotics given by injection. This drug is still investigational, but 
this study has been approved by the Federal Food and Drug Administra-
tion. 
The purpose of this study is to see how the drug, moxalactam, behaves 
in patients, as yourself, who have kidney disease requiring hemo-
dialysis. You will receive one dose of moxalactam by intravenous in-
jection within one day before hemodialysis. Blood samples will be 
taken from your arm before the antibiotic is given, and 5, 10, 15, 30 
minutes, and 1, 2, 4, 6, and 8 hours after the dose. One sample will 
be taken from your arm just prior to hemodialysis and one after hemo-
dialysis. Six samples will be taken from your blood during hemo-
dialysis as it is entering and leaving the dialyzer. Each blood sample 
will contain approximately 2-3 ml (about one-half teaspoonful). The 
total amount of blood drawn for the study will be about two ounces (60 
ml). Blood for 4 routine lab tests will be necessary also if your doc-
tor has not already ordered the tests. 
Some patients may experience mild discomfort when blood samples are 
taken. Other than this, you may experience only minimum discomfort 
during the study. You will be watched closely for any side effects you 
may experience. 
Although you may not receive any direct benefits from participation 
in this study, the information collected will help clinicians develop 
better dosing schedules for this drug when you or other patients may 
need this drug for treating an infection. 
You are under no obligation to participate in this study. Partici-
pation in this study may be ended at any time by withdrawing your consent 
without prejudice to your future care. 
Any questions that you have will be answered. 
In the event you sustain physical injury resulting from the research 
project in which you are participating, the University of Utah will pro-
vide you, without charge, emergency and temporary medical treatment not 
otherwise covered by insurance. Furthermore, if your injuries are 
caused by negligent acts or omissions of University employees acting in 
the course and scope of their employment, the University may be liable, 
subject to limitations prescribed by law, for additional medical costs 
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and other damages you sustain. If you believe that you have suffered 
a physical injury as a result of participation in this research program, 
please contact the Office of Research Administration, Phone No. 
581 -6903 . 
II. CONSENT 
I have read the foregoing and my questions have been answered. I 
desire to participate in this study. I give my permission for infor-
mation gathered in this study to be released to the prinicipal investi-
gator, Mary E. Russo, Pharm.D,, Department of Pharmacy Practice, and 
co-investigators Burton Janis, M.D., Division of Infectious Diseases, 
and Linda S. Tyler, Pharm.D. Candidate, Department of Pharmacy Practice, 
University of Utah Medical Center. 




ANTIBIOTIC ASSAY USING LARGE SQUARE PLATES FOR MOXALACTAM 
Seed Organism 
Escherichia coli ATCC 10536 (Lilly Research Laboratories) 
Medium Used 
Antibiotic Medium #1 (manufactured by Difco) 
Assay Plates 
Large 14 x 14 inch square glass plates with lids 
Antibiotic Standards 
All standards for serum samples were diluted in single donor 
serum (known donor). 
All standards for dialysate samples were diluted In normal saline 
Seed Organism Preparation 
E. coli broth suspension is prepared ahead and kept in the 
refrigerator until needed. 
To 250 ml of the media is added 0.75 ml of seed organism broth 
suspension. Swirl and pour into one large square glass plate 
allowing the plate to rest on a flat surface until the agar 
solidifies. 
ANTIBIOTIC ASSAY USING THE LARGE PLATES 
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( Square 14 x 14" Glass Plates ) 
1. Grow seed organisms up overnight if not ready. 
2. Prepare 250 ml of the appropriate antibiotic media early in the 
morning or make it the night before and melt it. 
3. While the media is melting or autoclaving read yesterdays run if 
one had been done. 
4. Once the media is melted or autoclaved place in water bath 56°C. 
5. Pre-warm the large 14 x 14" glass plate in an incubator (35°C). 
6. Get the moxalactam standards out and dilute them. 
7. Seed the cooled 250 ml agar (cooled to about 50°C) with the appro-
priate amount and organism to be used. Swirl and pour into the 
large plate that has been transferred to a flat surface at room 
temperature. 
8. While the agar plate is solidifying, which takes about one-half to 
one hour, start placing serum samples and controls on the discs 
that have been placed out on a large screen. Use tape on the 
screen to identify each sample. Make a template out of a large 
piece of mylar (this can be rubbed clean and used the next day). 
Use an Eppendorf pipetter (0.02 ml) or a variable Eppendorf 
pipetter or a similar pipetter to deliver 0.02 ml to each disc. 
Make five discs for each patient serum sample and five discs for 
each antibiotic standard. Discs to be used are blank Penicillin 
Assay discs one-fourth inch in diameter. To equalize results the 
discs need to dry and the time it takes for the agar to solidify 
is about right with Salt Lake City humidity. 
9. Make a paper template to indicate spots where the discs are to be 
located. It is best to have the mylar template line up with the 
paper template. 
10. Place discs on agar surface pressing down on each disc. 
11. Incubate level at 35°C overnight. 
12. lead zones of inhibition the next day and average the five zones 
for each patient's serum and average the five zones for each 
standard. Plot the standards on two cycle semi-log paper using 
a curve fitting program (Hewlett Packard HP-67) to determine the 
best fitting line. 
APPENDIX C 
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DEFINITION AND CALCULATION OF PHARMACOKINETIC PARAMETERS 
The following is a brief discussion of the definition and formulae 
used to calculate all of the parameters discussed. Wagner and 
Gibaldi give a more detailed explanation. 
I. ONE COMPARTMENT OPEN MODEL 
This model assumes instantaneous distribution into the body tissues. 
Because no definite distribution phase could be identified, this 
model was chosen to analyse the data from subject 1 .and the 
elimination rate constant and half-life during dialysis. The 
following is a list of definitions and derivations of parameters 
calculated; 
1. kel = elimination rate constant of first order kinetics. This is 
calculated from the negative slope of the line during elimina-
tion. This is the same as B of the two compartment model. 
2. tx = half-life of the drug is calculated as follows: 
-2 
t = 0-693 
h kel 
dos£ 3. V, = apparent volume of distribution = —z,— where C * d Cpo po 
plasma concentration at time zero. C p o is the y- intercept 
of the line used to calculate kel. 
4. Total body clearance is equal to kel x Vj and is also equal to 
dose/AUG 
cp vs t. 
5. AUC = area under the curve is mathematically equivalent to: 
, _ doS€i 
A cp vst = kel vd 
II. TWO COMPARTMENT OPEN MODEL 
This model is used when a distribution phase can be identified based 
on a graph of the data. This was an appropriate model for the data 
from subjects 2 through 7. 
1. g = beta = is the apparent first order elimination rate constant. 
It was derived graphically by determining the slope of the line 
of the terminal portion of the graph of the In Cp vs t. g is the 
negative slope of the line. 
2. B is the y intercept of the line that derived above with the 
slope 6. 
54 
3. a - alpha is the negative slope of the line derived by method 
of residuals (or feathering) representing the rate constant of 
the distribution phase. 
4. A is the y intercept of the line described above with the 
slope a. 
5. 1^ 21 = r a t e constant of the drug distributing from compartment 
2 to compartment 1. It is equal to: 
, = Ag + Bot 
21 A + B 
6. k^ Q is the rate constant representing drug going from compart-
ment 1 to outside the body. It is equal to: 
k 1 Q = aB = A + B ^ A/a + B/& 
7. k]_2 is the rate constant describing the rate of the drug moving 
from compartment 1 to compartment 2. It is equal to: 
k 1 2 = a + 6 - k 1 Q - k n 
As a rule the relationships below hold: 
k 1 0 >f3 
a >k21 >3 
8, Volume of distribution: In a two compartment model there are 
several volumes of distributuion, each representing a different 
part of the distribution characteristics of the drug described 
by a multicompartment model. 
V is the apparent volume of the central compartment, also 
denoted V^ . It is equal to: 
V = . , •v where Xn is equal to the dose, c A+ B ° 
V is the apparent volume relating to the amount of drug in the 
serum at steady state. It is equal to: 
V = k12 + k21 V ss k 21 
c 
V is the apparent volume of the peripheral compartment. It is 
^ equal to: 
V = V - V p ss c 
55 
V a r e a is the apparent volume of distribution of a drug that 
confers upon the body characteristic of a multicompartmental 
model. 
It is actually a proportionally constant that relates the amount 
of drug in the body to the drug concentration in the plasma at 
any time during the post distributive phase. It is equal to: 
V = vc k10 area 5 
V t is the extrapolated volume of distribution. It is equal to: 
V = dose = a - 3 V, 
— k ^ T 1 
The following relationships generally hold true: 
V > v > V > V ext area ss c 
9. Clearance (Cl) represents the rate the drug is cleared from the 
body. Mean body clearance and total body clearance are mathe-
matically equivalent. 
Cl = = V k. « V 0 AUC c 10 area 
10. AUC is equal to area under the curve. In the 2 compartment model 
AUC is equal to: 
AUCr „ = - + | Cp vs t a 0 
11. The half-life of the 0 and a phases can be calculated as for the 
1 compartment model. 
0 .693 tj* a = =5 a 
_ 0 .693 
\ B " 3 
APPENDIX D 
Half-life of cephalosporin antibiotics in 
patients with severe renal failure 
Cephalosporin Half-life (hr) 
In renal failure On dialysis 
Cephalothin 2.82 3.3 
12.00 
19.00 
Cephaloridine 22,45 4.3 
2,4 
Cephalexin 19,28 2.64 
18.20 3.60 
Cefazolin 39.81 14.25 
6.38 
Cephapirin 1.75 
Cephacetrile 22,10 4.7 
Cefoxitin 17.5 
Cefamandole 7.95 6.22 
Adapted from J Infect Pis 137:S90, 1978. 
APPENDIX E 
Moxalactam Minimum Inhibitory Concentration (MIC) 






Staph, aureus 4.5 2-16 
Staph, epidermidis 14.5 4->32 
Strep, spp. 2.3 0.3->64 
Escherichia coli 0.1 0.1-8.0 
Enterobacter spp. 0.3 0.1-16 
Klebsiella spp. 0.1 0.1-0.5 
Proteus mirabilis 0.1 0.1-0.3 
Proteus spp. (Indole +) 0.1 0.1 
Serratia marcescens 1.0 0.3-8.0 
Pseudomonas aeruginosa 16.0 8-32 
Neisseria gonorrhoeae 0.1 0.1 
Haemophilus influenzae 0.2 0.1-32 
Gram + anaerobic rods 1.9 0.3->64 
Gram + anaerobic cocci 0.2 0.1->64 
Gram - anaerobes 0.7 0.1-8.0 
Bacteroides fragilis 1.6 0.3-8.0 
Data compiled from Antimicrob Agents Chemother 17:412-16, 1980 
Andriole, V.T. 1978. Pharmacokinetics of cephalosporin anti-
biotics. J, Infect. Dis. 137S:S88-S97. 
Bennett, J.?., Brodie, J.L., Benner, E.J., Kirby, W.M.M.  1966. 
Simplified, accurate method for antibiotic assay of clinical 
specimens. Appl. Microbiol. 14:170-177. 
Bolton, W.K., Scheld, W.M., Spyker, D.A., Overby, T.L., Sande, 
M.A. 1980. Pharmacokinetics of moxalactam in subjects with 
various degrees of renal dysfunction. Antimicrob. Agents Chemo-
ther. 18:933-938. 
Burton, J.E., Lichtenstein, N.S., Colvin, R.B., Hyslop, N.E. Jr. 
1974. Acute renal failure during cephalothin therapy. J, Amer. 
Med. Assoc. 229:679-682. 
Carling, P.C., Idelson, B.A., Casano, A.A., Alexander, E.A., 
McCabe, W.R. 1975. Nephrotoxicity associated with cephalothin 
administration. Arch. Intern. Med. 135:797-801. 
Gibaldi, M., Perrier, D. 1975. Pharmacokinetics, p. 1-96, 175-188, 
253-266, 281-292. Marcel Dekker, Inc., New York. 
Lerner, P.I., Lubin, A. 1974, Coagulopathy with cefazolin in 
uremia. New Engl. J. Med. 290:1324. 
Natelson, E.A., Brown, C.H. Ill, Bradshae, M.W., Alfrey, C.P. Jr., 
Williams, T.W., Jr. 1976. Influence of cephalosporin antibiotics 
on blood coagulation and platelet function. Antimicrob. Agents 
Chemother. 9:91-93. 
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10. Reimer, L.G., Mirrett, S., Rel ler , L.B. 1980, Comparison of in 
vitro activity of moxalactam (LY127935) with eefazolin, amikacin, 
tobramycin, carbenicillin, piperacillin, and ticarcillin against 
420 blood culture isolates. Antimicrob. Agents Chemother. 17: 
412-416. 
11. Sanders, W.E., Johnson, J.E., Taggart, J.G. 1974. Adverse 
reactions to cephalothin and cephapirin. New Engl. J. Med. 290: 
424-429. 
12. Wagner, J.G. 1975. Fundamentals of Clinical Pharmacokinetics, 
p. 82-87. Drug Intelligence Publications, Inc., Hamilton, 
Illinois. 
13. Wu, M.J., Narsete, T.A. , Hussey, J.L., Weinstein, A.B., Wen, S.F. 
1978. Cephalothin neurotoxicity in renal failure. Ann. Intern. 
Med. 89:429. 
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